Delaware
|
001-38599
|
82-3827296
|
(State or Other Jurisdiction of Incorporation or Organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
AQST
|
Nasdaq Global Market
|
Item 1.01
|
Entry into a Material Contract
|
Item 9.01
|
Financial Statements and Exhibits
|
(d)
|
Exhibits.
|
Exhibit Number
|
Description
|
|
First Amendment to License Agreement, effective as of March 16, 2020, by and between Aquestive Therapeutics, Inc. and Sunovion Pharmaceuticals Inc. (formerly, Cynapsus Therapeutics,
Inc.)
|
Dated: March 20, 2020
|
Aquestive Therapeutics, Inc.
|
|
By:
|
/s/ John T. Maxwell
|
|
Name: John T. Maxwell
|
||
Title: Chief Financial Officer
|